University of Kentucky

UKnowledge
Pathology and Laboratory Medicine Faculty
Publications

Pathology and Laboratory Medicine

2011

Should Histologic Grade Be Incorporated into the TNM
Classification System for Small (T1, T2) Node-Negative Breast
Adenocarcinomas?
Matthew Purdom
University of Kentucky, mspurd0@pop.uky.edu

Michael L. Cibull
University of Kentucky, mcibull@pop.uky.edu

Terry D. Stratton
University of Kentucky, terry.stratton@uky.edu

Luis M. Samayoa
University of Kentucky, luis.samayoa@uky.edu

Edward Romond
University of Kentucky, ehromo1@uky.edu
Follow this and additional works at: https://uknowledge.uky.edu/pathology_facpub
See next page for additional authors
Part of the Pathology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Purdom, Matthew; Cibull, Michael L.; Stratton, Terry D.; Samayoa, Luis M.; Romond, Edward; McGrath,
Patrick C.; and Karabakhtsian, Rouzan G., "Should Histologic Grade Be Incorporated into the TNM
Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas?" (2011). Pathology and
Laboratory Medicine Faculty Publications. 9.
https://uknowledge.uky.edu/pathology_facpub/9

This Article is brought to you for free and open access by the Pathology and Laboratory Medicine at UKnowledge. It
has been accepted for inclusion in Pathology and Laboratory Medicine Faculty Publications by an authorized
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Should Histologic Grade Be Incorporated into the TNM Classification System for
Small (T1, T2) Node-Negative Breast Adenocarcinomas?
Digital Object Identifier (DOI)
http://dx.doi.org/10.4061/2011/825627

Notes/Citation Information
Published in Pathology Research International, v. 2011, article ID 825627, p. 1-4.
Copyright © 2011 Mathew Purdom et al. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.

Authors
Matthew Purdom, Michael L. Cibull, Terry D. Stratton, Luis M. Samayoa, Edward Romond, Patrick C.
McGrath, and Rouzan G. Karabakhtsian

This article is available at UKnowledge: https://uknowledge.uky.edu/pathology_facpub/9

SAGE-Hindawi Access to Research
Pathology Research International
Volume 2011, Article ID 825627, 4 pages
doi:10.4061/2011/825627

Research Article
Should Histologic Grade Be Incorporated into
the TNM Classification System for Small (T1, T2)
Node-Negative Breast Adenocarcinomas?
Mathew Purdom,1 Michael L. Cibull,1 Terry D. Stratton,2 Luis M. Samayoa,1
Edward H. Romond,3 Patrick C. Mcgrath,3 and Rouzan G. Karabakhtsian1
1 Department

of Pathology & Laboratory Medicine, Chandler Medical Center, College of Medicine, University of Kentucky,
800 Rose Street, MS 129, Lexington, KY 40536, USA
2 Department of Behavioral Sciences, University of Kentucky, Lexington, KY 40506, USA
3 Comprehensive Breast Care Center, Markey Cancer Center, Lexington, KY 40536, USA
Correspondence should be addressed to Rouzan G. Karabakhtsian, rkara2@email.uky.edu
Received 14 September 2010; Accepted 8 October 2010
Academic Editor: Rohit Bhargava
Copyright © 2011 Mathew Purdom et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Prognosis of invasive ductal carcinoma (IDC) strongly correlates with tumor grade as determined by Nottingham combined
histologic grade. While reporting grade as low grade/favorable (G1), intermediate grade/moderately favorable (G2), and high
grade/unfavorable (G3) is recommended by American Joint Committee on Cancer (AJCC) staging system, existing TNM (Primary
Tumor/Regional Lymph Nodes/Distant Metastasis) classification does not directly incorporate these data. For large tumors (T3,
T4), significance of histologic grade may be clinically moot as those are nearly always candidates for adjuvant therapy. However,
for small (T1, T2) node-negative (N0) tumors, grade may be clinically relevant in influencing treatment decisions, but data on
outcomes are sparse and controversial. This retrospective study analyzes clinical outcome in patients with small N0 IDC on the
basis of tumor grade. Our results suggest that the grade does not impact clinical outcome in T1N0 tumors. In T2N0 tumors,
however, it might be prognostically significant and relevant in influencing decisions regarding the need for additional adjuvant
therapy and optimal management.

1. Introduction
While the World Health Organization, College of American
Pathologist, and American Joint Commission on Cancer all
endorse reporting histologic tumor grade for IDC, it does not
directly factor into the current TNM staging system [1–3].
The Nottingham Combined Histologic Grade (NCHG), the
preferred grading system, stratifies tumors into three grades
based on semiquantitative evaluation of tubule formation,
nuclear pleomorphism, and mitoses [4]. Histologic tumor
grade, as determined by NCHG, correlates with prognosis [5]
and might represent a simple and inexpensive way to identify
low-risk patients who are highly curable by surgery alone or
are also in need of adjuvant therapy [6, 7]. Patients with large
tumors are almost always candidates for adjuvant therapy, so

incorporating histologic grade in such cases may be clinically
irrelevant [8]. Also, tumor size often correlates with tumor
grade [9]. In this era of mammographic screening, however,
an increasing proportion of identified breast cancers are
small and node negative. Whether or not histologic grade
is an independent prognostic factor in small, node-negative
IDC is still an unresolved question [10]. The Breast Task
Force of the AJCC has noted that the data on this issue
are sparse and inconsistent, and as such, it refrained from
directly including the histologic tumor grade into the
TNM staging. While the existing data clearly diﬀerentiate
the prognosis of G1 and G3 tumors, the behavior of G2
tumors is ambiguous owing to methodologic diﬀerences
(followup times, grading systems, and measured outcomes).
We undertook a retrospective study to analyze the clinical
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Table 1: Tumor stage, grade, and clinical outcome.

Alive without disease
Alive, status unknown
Alive with disease
Deceased without disease
Deceased, cause unknown
Deceased with disease
Total

G1
1
—
—
—
—
—
1

T1a (n = 10)
G2
G3
4
3
—
1
1
—
—
—
—
—
—
—
5
4

G1
5
—
—
—
—
1
6

T1b (n = 23)
G2
G3
10
5
1
—
—
—
1
—
—
—
—
—
12
5

G1
8
—
—
—
—
—
8

T1c (n = 45)
G2
20
—
—
1
—
—
21

G3
15
—
—
1
—
—
16

G1
1
—
—
—
—
—
1

T2 (n = 33)
G2
15
—
—
1
—
—
16

G3
11
—
1
1
—
3
16

G—tumor histologic grade.

Table 2: Clinical outcome by tumor grade in small (T1, T2) node-negative breast adenocarcinomas.
Tumor Size

Tumor Grade
G1-G2
G3

T1 (N = 76)∗
Clinical Outcome∗∗
Without Disease
With Disease
N
%
N
%
50
66
2
3
24
31
0
0

P ∗∗∗
.46

T2 (N = 33)
Clinical Outcome∗∗
Without Disease
With Disease
N
%
N
%
17
52
0
0
12
36
4
12

P ∗∗∗
.04

∗ Excludes

2 alive, status unknown.
∗∗ Clinical outcome includes patients living and deceased.
∗∗∗ The p-value is for a one-tailed Fisher exact test.

outcomes in patients with small, node-negative cancers in an
attempt to contribute to this ongoing debate regarding the
prognostic significance of histologic tumor grade.

2. Design
The files of the Department of Pathology, University of
Kentucky Medical Center were searched from January 1995
through July 2007 and yielded a total of 111 lumpectomy/mastectomy specimens from patients with T1N0 or
T2N0 tumor status. The cases included 10 T1a, 23 T1b, 45
T1c, and 33 T2 tumors. The age of patients ranged from
31 to 83 years (mean, 55 years). The length of followup
ranged from 7 to 152 months (mean, 56 months), with
at least 60 months (5 years) and longer followup in 56%
of patients. Presence of coexistent ductal carcinoma insitu (DCIS), lymphovascular invasion (LVI), estrogen and
progesterone receptor (ER/PR), and HER-2/neu status by
immunohistochemistry was analyzed. Clinical followup data
with outcome through year 2008 were obtained from Tumor
Registry. The tumor size and histologic grade in conjunction
with clinical outcome was analyzed.

3. Results
The data for tumor size, histologic grade, and patient status
are summarized in Table 1. On the followup of patients
with T1 tumors, 71/78 (93%) were alive and 3 deceased
without disease. Only one patient died with disease (G1/stage
T1b), and another patient was alive with disease recurrence (G2/stage T1a). Two patients were alive with status

unknown. Of the patients with T2 tumors, 27/33 (82%)
were alive and two deceased without disease on followup.
Three died with disease (all ER negative, including one triple
negative), and one was alive with disease; all four (12%)
had G3 tumors (including two with LVI). All patients with
hormone receptor positive tumor status received Tamoxifen
or aromatase inhibitors. Of patients with T1 tumors, 24%
received chemotherapy, as did 67% of patients with T2
tumors (2 of 4 with recurrent/ progressive disease had
chemotherapy).
Of T1 tumors, 76% (59/78) showed DCIS versus 69%
(22/32) in T2 tumors. LVI was identified in 3% (1/33) of
T1a/T1b, 13% (6/45) of T1c, and 24% (8/33) of T2 tumors.
Positive ER and PR status was reported in 71% (55/78) and
64% (50/78) of T1 tumors, respectively, and 63% (20/32) and
69% (22/32) of T2 tumors, respectively. All three deceased
patients with T2 tumors were tested ER negative. Two of
those three tumors also showed LVI. The patient with the
T1b tumor who died of disease had ER-positive tumor and
no LVI. HER-2/neu status was unknown in this case. Positive
HER-2/neu status was reported in 1/61 T1 tumors and 5/26
T2 tumors. Of three deceased cases, HER-2/neu status was
reported in only one and was negative. Both patients who are
alive with disease had positive ER and negative HER-2/neu
tumors, and no LVI.
The relationship between the tumor grade and clinical
outcome moderated by tumor size has been determined by
using the Fisher exact tests (Table 2).
The results of the Fisher exact tests suggest an interaction
eﬀect—with the relationship between tumor grade and
clinical outcome moderated by tumor size. That is, among
patients with T1 tumors (n = 76), clinical outcome did
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not vary significantly by tumor grade (P = .46). However,
among the T2 group (n = 33), the number of patients with
G3 tumors who were with disease (n = 4) was significantly
greater than those with G1-G2 tumors (n = 0)(P = .04). The
strength of the relationships (ϕ) between tumor grade and
clinical outcome for the T1 and T2 groups was.11 and.38,
respectively.

4. Discussion
Regardless of histologic grade, the overall prognosis for
small node-negative breast adenocarcinomas appears to be
very good. In the current study, the disease-free survival
for patients with T1N0 tumor status was 93% (71/76) and
for patients with T2N0 was 88% (29/33). This relatively
good prognosis is similar to that reported in prior studies
[5, 11, 12], and the diﬃculty of addressing the prognostic
significance of histologic grade in these breast cancers is
highlighted. Namely, studies would need to be larger to
have the statistical power to detect a relationship between
histologic grade and clinical outcomes. Beyond sample size,
length of followup is also an important consideration as
recurrence may occur quite late [13–15].
While some studies have shown histologic grade to
be prognostically significant in small, node-negative breast
carcinomas [5, 16, 17], other studies [18–20] do not demonstrate this association. Lundin et al. suggest that omission of
histologic grading from clinical decision making may result
in considerable overuse of adjuvant therapies [21]. Based on
our data in this relatively small study, there is no evidence
that higher tumor grade impacts the clinical outcome in
T1N0 tumors. This tumor status was not associated with
higher rate of recurrence or disease persistence in our study.
In T2 tumors, however, our data suggest that histologic
tumor grade might be prognostically significant and relevant
in influencing decisions regarding the need for additional
adjuvant therapy and optimal management of node-negative
breast carcinomas at this stage.
Currently, adjuvant hormonal and/or cytotoxic chemotherapies are recommended for most women with earlystage invasive breast cancer. Treatment decisions are based
on axillary node status, age, tumor size, histologic tumor
type, tumor grade, hormone receptor status, and coexisting
medical conditions [22]. However, most patients with nodenegative disease who receive chemotherapy will not derive
benefit because they would not go on to have a recurrence
even without such treatment, which also questions the
necessity of performing the Oncotype Dx testing in T1N0
tumors. New prognostic and predictive tests are needed to
better individualize therapy and confine systemic treatment,
especially cytotoxic chemotherapy, to those patients who are
most likely to benefit [23, 24]. Although based on a limited
material, our data may suggest more favorable prognosis for
patients with T1N0 regardless of tumor grade, as well as
low-grade T2N0 tumors, compared to those with high-grade
T2N0 disease who might benefit from additional chemotherapy. Larger studies with considerable statistical power will be
needed to definitively demonstrate the impact of histologic
grade in these subsets of breast adenocarcinoma.

3
Several relatively recent studies indicate that the histologic tumor grade appears to reflect specific molecular
predictive indicators such as proliferative markers and multigene expression arrays [25, 26]. Interestingly, the grading was
shown to correlate with other proposed prognostic factors
such as Recurrence Score (Oncotype Dx) and casting-type
microcalcifications [23, 24, 27]. In the Kaiser population,
tumor size and tumor grade remained statistically significant
associated with the risk of breast cancer death in most
multivariate models that also included the Recurrence Score
[23], whereas only tumor grade remained independently
associated with risk in the NCABP B-14 study [28]. The
Recurrence Score was able to identify a larger subset of
patients with low risk of breast cancer death than was
possible with either of the standard prognostic indicators
[23].
While currently the Breast Cancer Task Force has
elected not to include histologic grade as a stage-modifying
factor in the TNM system [8], it still does recommend
collection of tumor grade, using the standardized Nottingham combined histologic score with calibrated mitotic
counts, for inclusion in tumor registry database [1]. How
to merge histopathologic data with clinical, radiographic,
and molecular information into a therapeutic plan is an
evolving challenge. While many studies indicate the significance of Recurrence Score in predicting the magnitude of
chemotherapy benefit, given the financial constraints and
limited access to molecular testing within many health care
systems, studying the utility of histologic grade (along with
other parameters) continues to be relevant. For example,
based on the literature as well as our data, it might appear
that the Oncotype Dx testing (quoted price $4, 075 per
test) is adding little or no additional prognostic value to
T1N0 and low-grade T2N0 tumors, which almost always
show favorable outcome with no recurrence. Ultimately,
determining if histologic grade will independently provide
clinically relevant information in these cases to serve as a
decision tool in the adjuvant chemotherapy setting merits
further investigation with a large data set, extended followup,
and standardized reporting.
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